141 related articles for article (PubMed ID: 38191957)
1. Quantifying Site Burden to Optimize Protocol Performance.
Florez M; Smith Z; Olah Z; Martin M; Getz K
Ther Innov Regul Sci; 2024 Mar; 58(2):347-356. PubMed ID: 38191957
[TBL] [Abstract][Full Text] [Related]
2. Assessing the Financial Value of Decentralized Clinical Trials.
DiMasi JA; Smith Z; Oakley-Girvan I; Mackinnon A; Costello M; Tenaerts P; Getz KA
Ther Innov Regul Sci; 2023 Mar; 57(2):209-219. PubMed ID: 36104654
[TBL] [Abstract][Full Text] [Related]
3. Applying Systems Thinking to Inform Decentralized Clinical Trial Planning and Deployment.
Betcheva L; Kim JY; Erhun F; Oraiopoulos N; Getz K
Ther Innov Regul Sci; 2023 Sep; 57(5):1081-1098. PubMed ID: 37389795
[TBL] [Abstract][Full Text] [Related]
4. Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective.
de Jong AJ; Shahid N; Zuidgeest MGP; Santa-Ana-Tellez Y; Hogervorst M; Goettsch W; Traore H; de Boer A; Gardarsdottir H;
Value Health; 2024 Mar; 27(3):294-300. PubMed ID: 38043711
[TBL] [Abstract][Full Text] [Related]
5. The landscape of decentralized clinical trials (DCTs): focusing on the FDA and EMA guidance.
Park J; Huh KY; Chung WK; Yu KS
Transl Clin Pharmacol; 2024 Mar; 32(1):41-51. PubMed ID: 38586122
[TBL] [Abstract][Full Text] [Related]
6. Ethics review of decentralized clinical trials (DCTs): Results of a mock ethics review.
van Rijssel TI; de Jong AJ; Santa-Ana-Tellez Y; Boeckhout M; Zuidgeest MGP; van Thiel GJMW;
Drug Discov Today; 2022 Oct; 27(10):103326. PubMed ID: 35870693
[TBL] [Abstract][Full Text] [Related]
7. Assessing Patient Participation Burden Based on Protocol Design Characteristics.
Getz K; Sethuraman V; Rine J; Peña Y; Ramanathan S; Stergiopoulos S
Ther Innov Regul Sci; 2019 Aug; ():2168479019867284. PubMed ID: 31426692
[TBL] [Abstract][Full Text] [Related]
8. Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease Subgroups.
Getz K; Smith Z; Kravet M
Ther Innov Regul Sci; 2023 Jan; 57(1):49-56. PubMed ID: 35960455
[TBL] [Abstract][Full Text] [Related]
9. Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.
Izem R; Zuber E; Daizadeh N; Bretz F; Sverdlov O; Edrich P; Branson J; Degtyarev E; Sfikas N; Hemmings R
Ther Innov Regul Sci; 2024 May; 58(3):495-504. PubMed ID: 38315407
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Exploring the divergence in perspectives on clinical trial operations in South Korea during the COVID-19 pandemic: a comparison of a trial site and sponsors.
Kim YS; Kim A; Lee YS
Front Med (Lausanne); 2024; 11():1342184. PubMed ID: 38510454
[TBL] [Abstract][Full Text] [Related]
12. Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective.
Ghadessi M; Di J; Wang C; Toyoizumi K; Shao N; Mei C; Demanuele C; Tang RS; McMillan G; Beckman RA
Orphanet J Rare Dis; 2023 Apr; 18(1):79. PubMed ID: 37041605
[TBL] [Abstract][Full Text] [Related]
13. New Benchmarks Characterizing Growth in Protocol Design Complexity.
Getz KA; Campo RA
Ther Innov Regul Sci; 2018 Jan; 52(1):22-28. PubMed ID: 29714620
[TBL] [Abstract][Full Text] [Related]
14. Decentralized Clinical Trials in the Development of Drugs and Biological Products.
Robinson R; Sacks L
Ther Innov Regul Sci; 2024 Feb; ():. PubMed ID: 38305983
[TBL] [Abstract][Full Text] [Related]
15. Assessing Patient Participation Burden Based on Protocol Design Characteristics.
Getz K; Sethuraman V; Rine J; Peña Y; Ramanathan S; Stergiopoulos S
Ther Innov Regul Sci; 2020 May; 54(3):598-604. PubMed ID: 33301141
[TBL] [Abstract][Full Text] [Related]
16. Assessing the impact of protocol design changes on clinical trial performance.
Getz KA; Wenger J; Campo RA; Seguine ES; Kaitin KI
Am J Ther; 2008; 15(5):450-7. PubMed ID: 18806521
[TBL] [Abstract][Full Text] [Related]
17. Enhancing asthma research and improving health equity through decentralized clinical trials (DCTs) and mHealth technology.
Hunt ER; Hantgan SL; Jariwala SP
J Asthma; 2024 Apr; 61(4):265-270. PubMed ID: 37787433
[TBL] [Abstract][Full Text] [Related]
18. A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs).
Coyle J; Rogers A; Copland R; De Paoli G; MacDonald TM; Mackenzie IS;
Trials; 2022 Jul; 23(1):614. PubMed ID: 35907888
[TBL] [Abstract][Full Text] [Related]
19. Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective.
de Jong AJ; van Rijssel TI; Zuidgeest MGP; van Thiel GJMW; Askin S; Fons-Martínez J; De Smedt T; de Boer A; Santa-Ana-Tellez Y; Gardarsdottir H;
Clin Pharmacol Ther; 2022 Aug; 112(2):344-352. PubMed ID: 35488483
[TBL] [Abstract][Full Text] [Related]
20. Legal, Regulatory, and Practical Issues to Consider When Adopting Decentralized Clinical Trials: Recommendations From the Clinical Trials Transformation Initiative.
Apostolaros M; Babaian D; Corneli A; Forrest A; Hamre G; Hewett J; Podolsky L; Popat V; Randall P
Ther Innov Regul Sci; 2020 Jul; 54(4):779-787. PubMed ID: 32557302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
